InvestorsHub Logo
Followers 134
Posts 3756
Boards Moderated 0
Alias Born 01/28/2006

Re: farrell90 post# 248566

Tuesday, 11/13/2018 9:44:36 PM

Tuesday, November 13, 2018 9:44:36 PM

Post# of 403507
Nice summary of Brilacidin for Ulcerative Proctitis.

The poster board presentation provides more detail of the FDA stage 2 study of Brilacidin for UP:

It was shown to be effective for UP

Impressive post treatment colonscopy pictures

The positive effect was dose related

A high rate of complete remissions was obtained

It shown to be safe,no SAE's

Minimal systemic absorption

16 0f 17 study patients showed a significant improvement in their quality of life.

Inflammatory bowel disease is common with estimates as high as 1.3 million Americans being effected.

https://www.cdc.gov/ibd/ibd-epidemiology.htm

It's not surprising a global pharmaceutical company confirmed its interest in Brilacidin for by signing a nonbinding term sheet which includes Brilacidin for IBD.

"The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet".

GLTA, Farrell
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News